NDASUBCUTANEOUSINJECTABLE
Approved
Mar 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
2/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMLIN (pramlintide acetate) is an amylin analog administered via subcutaneous injection that slows gastric emptying and suppresses glucagon secretion to improve postprandial glycemic control. It is indicated as an adjunct therapy for patients with type 1 and type 2 diabetes already on insulin therapy. The drug mimics the natural hormone amylin, which is deficient in diabetic patients.
LOE Approaching
With LOE approaching, SYMLIN is transitioning from growth to decline phase; commercial teams should expect consolidation of field footprint and shift toward retention and lifecycle extension efforts.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Started Feb 2010
22 enrolled
HypoglycemiaEvidence of Previous Gastric Surgery
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
Started May 2007
112 enrolled
Type 2 Diabetes Mellitus
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
Started Apr 2006
12 enrolled
Type 1 Diabetes Mellitus
A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
Started Oct 2005
200 enrolled
Type 2 Diabetes Mellitus
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
Started Sep 2005
1,297 enrolled
Type 1 Diabetes MellitusType 2 Diabetes Mellitus
Worked on SYMLIN at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.